Chapter 85: Treatment and Prevention of Bone Metastases and Myeloma Bone Disease Jean-Jacques Body

Figure 1 Figure 1 Analgesic activity of long-term therapy with bisphosphonates in placebo-controlled trials. Effects of zoledronic acid (Zole) are shown in left panels (pain assessed by the Brief Pain Inventory score, quantitative 10-point scale): top, breast cancer; bottom, prostate cancer. Effects of ibandronate (Iban) in breast cancer are shown in the right panels (pain assessed on a qualitative five-point scale): top, intravenous route; bottom, oral route. © 2008 American Society for Bone and Mineral Research From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7 th Edition.

Figure 2 Figure 2 Effects of long-term therapy with bisphosphonates on the risk of developing a skeletal complication in patients with bone metastases. Data are summarized by a multiple-event analysis (Andersen-Gill model for zoledronic acid and Poisson regression analysis for ibandronate). Hazard ratios (and 95% CI) are shown in the left part of each graph with corresponding p values indicated in the right parts. © 2008 American Society for Bone and Mineral Research From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7 th Edition.